<DOC>
	<DOC>NCT01652937</DOC>
	<brief_summary>Phase II study designed to evaluate the safety and efficacy of BIIB057 in Subjects with Rheumatoid Arthritis who have experienced an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs).</brief_summary>
	<brief_title>BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult onset RA satisfying 2010 Revised ACR Criteria for the Classification of RA with a disease history of at least 6 months Active RA as defined by: at least 4 swollen joints (based on 28joint count), at least 4 tender joints (based on 28joint count), and highsensitivity CRP (hsCRP) 10mg/L or greater No prior treatment with biologics Receiving a DMARD therapy for at least 3 months, using a regimen that has been stable for at least 28 days prior to screening History of inflammatory joint disease other than RA Abnormal chest Xray consistent with tuberculosis, malignancy, or infection History of malignancy, carcinoma in situ, or highgrade dysplasia History of opportunistic infection, infection requiring treatment, serious local infection, recent fever, active herpes zoster or EpsteinBarr virus, or diagnosis or family history of CreutzfeldtJakob disease. Clinically significant cardiac disease Treatment with prednisone &gt;10 mg orally daily Intraarticular steroid injection within 28 days before screening Clinically significant abnormality in hematology or blood chemistry values at screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>DMARD-IR</keyword>
</DOC>